Sodium butyrate in Irritable Bowel Syndrome
DOI:
https://doi.org/10.12775/JEHS.2025.82.60166Keywords
sodium butyrate, irritable bowel syndrome, ibsAbstract
Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder characterized by abdominal pain, bloating, and altered bowel habits. Although its pathophysiology is not fully understood, factors such as gut microbiota imbalance, increased intestinal permeability, and low-grade inflammation are considered key contributors. Sodium butyrate, a short-chain fatty acid produced by bacterial fermentation of dietary fiber, plays an important role in gut health. It supports intestinal barrier function, reduces inflammation, and influences microbiota composition. This review summarizes current knowledge on the role of sodium butyrate in IBS, focusing on its mechanisms of action and clinical relevance. A literature review was conducted using databases such as PubMed and Google Scholar with relevant MeSH keywords. Preclinical and clinical studies indicate that sodium butyrate may help alleviate IBS symptoms by enhancing epithelial integrity and modulating inflammation. However, variations in study design and dosing limit clear conclusions. Further randomized trials are needed to confirm its efficacy and define optimal treatment strategies.
References
1. Altomare A, Di Rosa C, Imperia E, Emerenziani S, Cicala M, Guarino MPL. Diarrhea predominant-irritable bowel syndrome (Ibs-d): Effects of different nutritional patterns on intestinal dysbiosis and symptoms. Vol. 13, Nutrients. MDPI; 2021.
2. Hanning N, Edwinson AL, Ceuleers H, Peters SA, De Man JG, Hassett LC, et al. Intestinal barrier dysfunction in irritable bowel syndrome: a systematic review. Vol. 14, Therapeutic Advances in Gastroenterology. SAGE Publications Ltd; 2021.
3. Orlando A, Tutino V, Notarnicola M, Riezzo G, Linsalata M, Clemente C, et al. Improved symptom profiles and minimal inflammation in IBS-d patients undergoing a long-term low-fodmap diet: A lipidomic perspective. Nutrients. 2020 Jun 1;12(6).
4. Zheng T, Eswaran S, Photenhauer AL, Merchant JL, Chey WD, D’Amato M. Reduced efficacy of low FODMAPs diet in patients with IBS-D carrying sucrase-isomaltase (SI) hypomorphic variants. Vol. 69, Gut. BMJ Publishing Group; 2020. p. 397–8.
5. Cangemi DJ, Lacy BE. Management of irritable bowel syndrome with diarrhea: a review of nonpharmacological and pharmacological interventions. Vol. 12, Therapeutic Advances in Gastroenterology. SAGE Publications Ltd; 2019.
6. Canakis A, Haroon M, Weber HC. Irritable bowel syndrome and gut microbiota. Vol. 27, Current Opinion in Endocrinology, Diabetes and Obesity. Lippincott Williams and Wilkins; 2020. p. 28–35.
7. Lacy BE, Pimentel M, Brenner DM, Chey WD, Keefer LA, Long MD, et al. ACG Clinical Guideline: Management of Irritable Bowel Syndrome. American Journal of Gastroenterology. 2021 Jan 1;116(1):17–44.
8. Kay E, Hawramee S, Pollani S, Mandel ED. Nonpharmacologic options for treating irritable bowel syndrome. J Am Acad Physician Assist. 2019 Mar 1;32(3):38–42.
9. Głąbień M, Miłkowski P, Kuśnierz A, Kusiak K, Aleksandrowicz D, Wieczorek O, et al. Sodium Butyrate as Gut Microbiota Modulators: Mechanisms of Action and Potential Clinical Applications - Literature Review and New Perspectives. Quality in Sport [Internet]. 2024 Oct 23;27:55233. Available from: https://apcz.umk.pl/QS/article/view/55233
10. Chen G, Ran X, Li B, Li Y, He D, Huang B, et al. Sodium Butyrate Inhibits Inflammation and Maintains Epithelium Barrier Integrity in a TNBS-induced Inflammatory Bowel Disease Mice Model. EBioMedicine. 2018 Apr 1;30:317–25.
11. Siddiqui MT, Cresci GAM. The Immunomodulatory Functions of Butyrate. Vol. 14, Journal of Inflammation Research. Dove Medical Press Ltd; 2021. p. 6025–41.
12. Otani T, Furuse M. Tight Junction Structure and Function Revisited. Vol. 30, Trends in Cell Biology. Elsevier Ltd; 2020. p. 805–17.
13. Zhang Y, Zhang B, Dong L, Chang P. Potential of Omega-3 Polyunsaturated Fatty Acids in Managing Chemotherapy- or Radiotherapy-Related Intestinal Microbial Dysbiosis. Vol. 10, Advances in Nutrition. Oxford University Press; 2019. p. 133–47.
14. Nozu T, Miyagishi S, Nozu R, Takakusaki K, Okumura T. Butyrate inhibits visceral allodynia and colonic hyperpermeability in rat models of irritable bowel syndrome. Sci Rep. 2019 Dec 1;9(1).
15. Sitkin S, Vakhitov T, Pokrotnieks J. Oral butyrate modulates the gut microbiota in patients with inflammatory bowel disease, most likely by reversing proinflammatory metabolic reprogramming of colonocytes. Vol. 33, Neurogastroenterology and Motility. Blackwell Publishing Ltd; 2021.
16. Zhuang X, Tian Z, Li L, Zeng Z, Chen M, Xiong L. Fecal microbiota alterations associated with diarrhea-predominant irritable bowel syndrome. Front Microbiol. 2018 Jul 25;9(JUL).
17. Duan R, Zhu S, Wang B, Duan L. Alterations of gut microbiota in patients with irritable bowel syndrome based on 16s rRNA-targeted sequencing: A systematic review. Vol. 10, Clinical and Translational Gastroenterology. Lippincott Williams and Wilkins; 2019.
18. Duan R, Zhu S, Wang B, Duan L. Alterations of gut microbiota in patients with irritable bowel syndrome based on 16s rRNA-targeted sequencing: A systematic review. Vol. 10, Clinical and Translational Gastroenterology. Lippincott Williams and Wilkins; 2019.
19. Presti A Lo, Zorzi F, Chierico F Del, Altomare A, Cocca S, Avola A, et al. Fecal and mucosal microbiota profiling in irritable bowel syndrome and inflammatory bowel disease. Front Microbiol. 2019;10(JULY).
20. Rosca AE, Iesanu MI, Zahiu CDM, Voiculescu SE, Paslaru AC, Zagrean AM. Capsaicin and gut microbiota in health and disease. Vol. 25, Molecules. MDPI AG; 2020.
21. Fu X, Liu Z, Zhu C, Mou H, Kong Q. Nondigestible carbohydrates, butyrate, and butyrate-producing bacteria. Vol. 59, Critical Reviews in Food Science and Nutrition. Taylor and Francis Ltd.; 2019. p. S130–52.
22. Pietrzak A, Banasiuk M, Szczepanik M, Borys-Iwanicka A, Pytrus T, Walkowiak J, et al. Sodium Butyrate Effectiveness in Children and Adolescents with Newly Diagnosed Inflammatory Bowel Diseases—Randomized Placebo-Controlled Multicenter Trial. Nutrients. 2022 Aug 1;14(16).
23. Cremon C, Guglielmetti S, Gargari G, Taverniti V, Castellazzi AM, Valsecchi C, et al. Effect of Lactobacillus paracasei CNCM I-1572 on symptoms, gut microbiota, short chain fatty acids, and immune activation in patients with irritable bowel syndrome: A pilot randomized clinical trial. United European Gastroenterol J. 2018 May 1;6(4):604–13.
24. Mazzawi T, Hausken T, Hov JR, Valeur J, Sangnes DA, El-Salhy M, et al. Clinical response to fecal microbiota transplantation in patients with diarrhea-predominant irritable bowel syndrome is associated with normalization of fecal microbiota composition and short-chain fatty acid levels. Scand J Gastroenterol. 2019 Jun 3;54(6):690–9.
25. Gargari G, Taverniti V, Gardana C, Cremon C, Canducci F, Pagano I, et al. Fecal Clostridiales distribution and short-chain fatty acids reflect bowel habits in irritable bowel syndrome. Environ Microbiol. 2018 Sep 1;20(9):3201–13.
26. Tian Z, Zhuang X, Luo M, Yin W, Xiong L. The propionic acid and butyric acid in serum but not in feces are increased in patients with diarrhea-predominant irritable bowel syndrome. BMC Gastroenterol. 2020 Mar 16;20(1).
27. Pietrzak A, Banasiuk M, Szczepanik M, Borys-Iwanicka A, Pytrus T, Walkowiak J, et al. Sodium Butyrate Effectiveness in Children and Adolescents with Newly Diagnosed Inflammatory Bowel Diseases—Randomized Placebo-Controlled Multicenter Trial. Nutrients. 2022 Aug 1;14(16).
28. Vancamelbeke M, Laeremans T, Vanhove W, Arnauts K, Ramalho AS, Farré R, et al. Butyrate Does Not Protect against Inflammation-induced Loss of Epithelial Barrier Function and Cytokine Production in Primary Cell Monolayers from Patients with Ulcerative Colitis. J Crohns Colitis. 2019 Sep 27;13(10):1351–61.
29. Banasiewicz T, Domagalska D, Borycka-Kiciak K, Rydzewska G. Determination of butyric acid dosage based on clinical and experimental studies-a literature review. Vol. 15, Przeglad Gastroenterologiczny. Termedia Publishing House Ltd.; 2020. p. 119–25.
30. Facchin S, Vitulo N, Calgaro M, Buda A, Romualdi C, Pohl D, et al. Microbiota changes induced by microencapsulated sodium butyrate in patients with inflammatory bowel disease. Neurogastroenterology and Motility. 2020 Oct 1;32(10).
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Aleksandra Kołodziej, Wiktoria Zamirska, Nadia Hornig, Aleksandra Cieplak, Zuzanna Czyżewicz
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 783
Number of citations: 0
